1 / 18

Updates on CDISC Activities

Updates on CDISC Activities. Sergiy Sirichenko. DC CDISC User Group Meeting, DC, 2014-03-20. Outlines. Standards Updates SDTM 1.4/IG3.2 Therapeutics: Multiple Sclerosis, Alzheimer, MCI and Asthma Dataset-XML CDASH SAE Updates from FDA

skylar
Download Presentation

Updates on CDISC Activities

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Updates on CDISC Activities Sergiy Sirichenko DC CDISC User Group Meeting, DC, 2014-03-20

  2. Outlines • Standards Updates • SDTM 1.4/IG3.2 • Therapeutics: Multiple Sclerosis, Alzheimer, MCI and Asthma • Dataset-XML • CDASH SAE • Updates from FDA • New FDA Guidances on Standard Data for Electronic Submissions • Define.xml v2 • SI units • Upcoming events • CDISC Interchanges and User Groups • PharmaSUG • Other

  3. New SDTM version • December, 2013 • http://www.cdisc.org/sdtm • SDTM v1.4 • Version of new SDTM IG is 3.2, rather than 3.1.4 • New design of SDTM IG document as PDF portfolio  • New IG-AP describes how to handle data about • Devices • “Associated persons” who are not study subjects • New variables were added into SDTM model • New special purpose domains • 11 new domains in IG

  4. New domains in SDTM IG 3.2 • Interventions • EC – Exposure as Collected • PR – Procedures • Events • HO – Healthcare Encounters • Findings • DD – Death Details • IS – Immunogenicity Specimen Assessment • MI – Microscopic Findings • MO – Morphology • RP – Reproductive System Findings • SS – Subject Status • SR – Skin Response • Trial Design • TD – Trial Disease Assessment

  5. UG for Multiple Sclerosis V1.0 • February, 2014 • http://www.cdisc.org/therapeutic • Draft version 1.0 based on SDTM v1.4 • Comments Due April, 1st • Examples use the following SDTM domains • Examples cover

  6. UG for Alzheimer’s Disease and Mild Cognitive Impairment V2.0 • December, 2013 • http://www.cdisc.org/therapeutic • Provisional version Based on SDTM v1.4 • Examples are added for CSF biomarker and imaging biomarkers endpoints • QS Terminology • Ten additional clinical scales relevant to AD and MCI • Examples are adjusted with new SDTM/SDTM IG versions; • Family History examples moved from MH to APMH (Associated Persons Medical History) domain • ApoE genetics data examples are moved from SC to PF (Pharmacogenomics Findings) domain

  7. Therapeutic Area Data Standards User Guide for Asthma v1.0 • November, 2013 • http://www.cdisc.org/therapeutic • Provisional version based on SDTM v1.4 • Examples use the following SDTM domains • AG – Procedure Agents** • CM – Concomitant Medications • AE – Adverse Events • HO – Healthcare Encounters* • MH – Medical History • LB – Laboratory Test Results • RE – Respiratory System Findings** • FA – Findings About • SR – Skin Response* • DI – Device Identifier* • DU – Device-in-Use* • Note: * Domain is new in SDTMIG v3.2; **Domain was not published in SDTMIG v3.1.3 and is not final.

  8. http://www.cdisc.org/stuff/contentmgr/files/0/2356ae38ac190ab8ca4ae0b222392b37/misc/cfast_ta_program_overview_february_2014.pdfhttp://www.cdisc.org/stuff/contentmgr/files/0/2356ae38ac190ab8ca4ae0b222392b37/misc/cfast_ta_program_overview_february_2014.pdf

  9. CDASH Serious Adverse Event Supplement Version 1 November, 2013 http://www.cdisc.org/cdash Final version Extends AE domain to include data elements needed for SAE info Will allow the sponsor to generate E2B message for reporting ICSR Allows to skip data re-entry

  10. Dataset-XML Specification V1.o November, 2013 http://portal.cdisc.org/CT/Review%20Documents/Forms/AllItems.aspx Dataset-XML Was developed as an alternative to SAS Xport Require define.xml to read data FDA is running an evaluation pilot

  11. All “CDISC Standards Latest Updates” http://www.cdisc.org/

  12. New FDA Guidances on Standard Data for Electronic Submissions Study Data Technical Conformance Guide and Data Standards Catalog Guidance on Electronic Submissions: Standardized Study Data Guidance on Submissions in Electronic Format--Submissions under the Federal Food, Drug, and Cosmetic Act February, 2014 Draft Guidance 90 days period for public comments

  13. Study Data Technical Conformance Guide • New expected documents • Study Data Standardization Plan • Study Data Reviewer’s Guide • Additional requirements. E.g., • “The Subject Elements domain should be included…” • “The AE domain should include all adverse events that were recorded in the subjects’ case report forms, regardless of whether the sponsor determined that particular events were or were not treatment-emergent.” • New Sections. E.g., #8. Data Fitness • Study Data Validation Rules • Conformance (data standards) • Quality (support meaningful analysis) • Study Data Traceability • Legacy Data Conversion Plan and Report • aCRFs for legacy data elements • “Record significant data issues, clarifications, explanations of traceability, and adjudications in the Data Guide”

  14. CDER/CBER Position on Use of SI Units for Lab Tests October, 2013 http://www.fda.gov/ForIndustry/DataStandards/StudyDataStandards/ucm372553.htm “CDER and CBER are evaluating an approach to transition to general acceptance of laboratory data in clinical trials that are measured and reported in Système International (SI) units instead of U.S. Conventional units. The objective is to establish an agency-wide policy on the acceptance of SI units in product submissions. … While this evaluation is underway, sponsors are strongly encouraged to solicit input from review divisions as early in the development cycle as possible to minimize the potential for conversion needs during NDA/BLA review. CDER and CBER encourage sponsors to discuss this issue with FDA before the start of Phase 3 trials.  In some cases the issue may warrant discussion with FDA at the End-of-Phase 2 meeting. …”

  15. FDA is now accepting Define.xml v2.0 http://www.fda.gov/ForIndustry/DataStandards/StudyDataStandards/default.htm

  16. CDISC Meetings 2014 Interchange • Europe : April, 7th - 11th, Paris, France • USA: November, 10th – 14th, North Bethesda, MD Use Groups • Boston: March, 28th, hosted by PAREXEL, Bilirica, MA • Oncology Area Standards • CDISC End-to-End • Atlantic: April, 17th, hosted by Celgene, Summit, NJ • 6 presentations • Webex available Details including agenda and registration info on http://cdiscportal.digitalinfuzion.com/CDISC%20User%20Networks/default.aspx

  17. PharmaSUG • June 1st-4th, San Diego, CA • http://www.pharmasug.org/us/index.html • The Pharmaceutical Industry SAS® Users Group Annual Conference • Online Registration is open • Lowest fees until April, 28th • Paper abstracts are published • Special “Data Standards” section (19 papers)

  18. Other • Instem is sharing their sample SEND data • Contact Jennifer Feldmannsubmit@instem.com for details. Inlcude "Send me SEND" in the subject  • New OpenCDISC release in March will support • SDTM IG3.2 • Define.xml v2.0 • Dataset-XML

More Related